Humana Medicare Advantage: Strategy & Concerns
- Humana executives are vigorously defending Medicare Advantage (MA) as the program faces increased calls for reform.
- Despite historical bipartisan support, MA has come under scrutiny amid concerns about potential waste, fraud, and abuse. Critics allege that major insurers are manipulating the system to boost...
- Humana CEO Jim Rechtin argues that concerns surrounding payer practices like risk adjustment, home assessments, and prior authorizations are overblown, though he conceded thereS room for advancement.
Humana is aggressively defending its Medicare Advantage (MA) plans amidst mounting calls for reform, emphasizing the benefits for seniors and taxpayers. The insurer is navigating scrutiny over concerns about potential fraud and abuse within the Medicare Advantage system and the impact on healthcare costs. Executives argue that practices like risk adjustment and prior authorizations are essential, even as they acknowledge areas for betterment. Humana, with a important stake in MA, faces financial challenges while regulators increase scrutiny. News Directory 3 provides insights into humana’s strategies,including efforts to improve star ratings and expand into Medicaid. Discover what’s next for Humana and its Medicare Advantage plans.
Humana Defends Medicare Advantage Amid Reform Calls
Humana executives are vigorously defending Medicare Advantage (MA) as the program faces increased calls for reform. The insurer insists that MA, which serves over half of all Medicare beneficiaries through private payer contracts, ultimately benefits both seniors and taxpayers by improving care coordination and outcomes.
Despite historical bipartisan support, MA has come under scrutiny amid concerns about potential waste, fraud, and abuse. Critics allege that major insurers are manipulating the system to boost profits, leading to delayed or denied care and inflated goverment payments.
Humana CEO Jim Rechtin argues that concerns surrounding payer practices like risk adjustment, home assessments, and prior authorizations are overblown, though he conceded thereS room for advancement. He defended these tools as essential for clinical care and cost control, emphasizing the need for responsible implementation.
Humana, with 6 million MA members, has a strong financial stake in the program’s stability, as MA premiums accounted for $24.1 billion of its $27.8 billion total last year.However,the insurer has faced profit challenges due to rising medical costs and regulatory changes.
Reports indicate that MA insurers may be overpaid by billions annually due to upcoding, where diagnosis codes are manipulated to exaggerate health needs. Such as, MedPAC estimates that CMS will pay MA insurers $84 billion more this year than if those members were in traditional medicare.
Home assessments, where clinicians visit patients at home, have also drawn criticism. While insurers claim these visits improve care and identify unmet needs, a Wall Street Journal examination found they contribute to inflated revenue through increased diagnoses.
Rechtin stated Humana will not invest in “chasing diagnosis codes that don’t drive the system to a better place.” Regarding prior authorization, Humana’s insurance president, George Renaudin, acknowledged the friction it creates and said the company is working to streamline the process.
Despite insurer resistance, regulators and lawmakers are paying attention to MA concerns. Although potential MA reforms were considered in the Senate, preliminary text from the Senate Finance Committee doesn’t propose any changes to Medicare.
Rechtin acknowledged the political challenges, stating, “the immovable object are seniors who vote,” noting their strong support for Medicare Advantage. Renaudin cited a survey showing that 9 in 10 senior voters consider a candidate’s support for MA crucial.
Beyond legislative action, regulators are also increasing scrutiny. CMS plans to increase MA plan payment audits and expedite reviews.Renaudin declined to comment on retroactive audits, citing ongoing litigation, but noted Humana proactively deletes unsupported codes.
Humana’s investor day, held in Louisville, Kentucky, focused on improving margins by 2028, including boosting MA star ratings. A drop in Humana’s average star rating for 2025 is projected to cost the payer $1 billion to $3 billion in 2026. Despite legal challenges, Humana is planning for the possibility of losing its lawsuit.
While projecting possibly shrinking earnings in 2026, Humana doesn’t plan to cut benefits. The company is also pursuing growth in Medicaid and its CenterWell health services division, including acquiring more primary care practices.
“It is not lost on us that the core of our business is Medicare Advantage,” Rechtin said. “When medicare Advantage doesn’t work, the rest of our business struggles. And so we need Medicare Advantage to work.”